Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso.
BACKGROUND
In sub-Saharan Africa, 112 million people are infected with Schistosoma haematobium, with the most intense infections in children 5-15 years old.


METHODS
We describe a longitudinal epidemiological study that evaluates the relationship between S. haematobium infection and associated morbidity in children before and after the large-scale administration of praziquantel for schistosomiasis and albendazole for soil-transmitted helminths.


RESULTS
At baseline, higher intensities of S. haematobium infection were observed in children with anemia and/or severe microhematuria, but there was no apparent association between the risk of undernutrition and intensity of S. haematobium infection. Significant reductions in the prevalence and intensity of S. haematobium infection 1 year after treatment were, however, observed. Children who benefited the most from anthelmintic treatment in terms of increased hemoglobin concentrations were those who had anemia at baseline and those with highly positive microhematuria scores at baseline.


CONCLUSIONS
This study suggests that even a single round of mass chemotherapy can have a substantial impact on S. haematobium infection and its associated morbidity in children.
Koukounari
Artemis
A
Schistosomiasis Control Initiative, Department of Infectious Disease Epidemiology, Imperial College London, London, W2 1PG, United Kingdom. artemis.koukounari@imperial.ac.uk
Gabrielli
Albis F
AF
Toure
Seydou
S
Bosque-Oliva
Elisa
E
Zhang
Yaobi
Y
Sellin
Bertrand
B
Donnelly
Christl A
CA
Fenwick
Alan
A
Webster
Joanne P
JP
D000293:Adolescent; D000740:Anemia; D002050:Burkina Faso / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005243:Feces / Q000469:parasitology; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D011223:Praziquantel / Q000627:therapeutic use*; D012553:Schistosomiasis haematobia / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D012556:Schistosomicides / Q000627:therapeutic use*
D012556:Schistosomicides; D011223:Praziquantel